Accéder au contenu
MilliporeSigma
Toutes les photos(2)

Documents

RAB0484

Sigma-Aldrich

Human Osteoprotegerin / TNFRSF11b ELISA Kit

for serum, plasma, cell culture supernatant and urine

Synonyme(s) :

OPG

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
41116158
Nomenclature NACRES :
NA.32

Espèces réactives

human

Conditionnement

kit of 96 wells (12 strips x 8 wells)

Technique(s)

ELISA: suitable
capture ELISA: suitable

Entrée

sample type serum
sample type urine
sample type cell culture supernatant(s)
sample type plasma

assay range

inter-assay cv: <12%
intra-assay cv: <10%
sensitivity: 1 pg/mL
standard curve range: 1.23-900 pg/mL

Méthode de détection

colorimetric

Conditions d'expédition

wet ice

Température de stockage

−20°C

Informations sur le gène

Description générale

The Human Osteoprotegerin ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human Osteoprotegerin in serum, plasma, cell culture supernatants and urine.

Osteoprotegerin (OPG) is encoded by the gene mapped to human chromosome 8q24. It is a member of the TNFR (tumor necrosis factor receptor) superfamily that can act as a decoy receptor for RANKL (receptor activator of nuclear factor kappa-B ligand) and TRAIL (tumor necrosis factor-related apoptosis-inducing ligand). OPG is expressed in a wide variety of tissues, including adult heart, lung, kidney and liver. It is secreted both as a monomeric and a dimeric protein.

Immunogène

Recombinant Human OPG

Application

For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)

Actions biochimiques/physiologiques

Binding of soluble osteoprotegerin (OPG) to sRANKL (soluble receptor activator of nuclear factor κ-B ligand) inhibits osteoclastogenesis by interrupting the signaling between stromal cells and osteoclastic progenitor cells. This process leads to excess accumulation of bone and cartilage. Changes in the level of serum OPG are associated with atherosclerosis and cardiovascular disorders(CVDs). It might also be associated with malignancy and plays a regulatory role in multiple myeloma, prostate, breast, bladder and gastric carcinoma. OPG plays a vital role in bone metabolism and is involved in inhibition of ovariectomy-associated bone loss in rats. It is also used as a potent biomarker for CVD.

Autres remarques

A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.

Composants de kit également disponibles séparément

Réf. du produit
Description
FDS

  • RABELADAELISA 1X Assay/Sample Diluent Buffer A (Item D1)FDS

  • RABELADBELISA 5X Assay/Sample Diluent Buffer B (Item E1)FDS

  • RABSTOP3ELISA Stop Solution (Item I)FDS

  • RABTMB3ELISA Colorimetric TMB Reagent (HRP Substrate, Item H)FDS

  • RABWASH420X Wash Buffer (Item B)FDS

Pictogrammes

Corrosion

Mention d'avertissement

Warning

Mentions de danger

Conseils de prudence

Classification des risques

Met. Corr. 1

Code de la classe de stockage

8A - Combustible corrosive hazardous materials


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Allison P Garcia et al.
Journal of clinical pharmacology, 60(2), 209-217 (2019-09-20)
This pilot study examined how exemestane (an aromatase inhibitor [AI]) affected osteoprotegerin (OPG) urine concentrations in postmenopausal women. Exemestane (25 mg, single dose) was given to 14 disease-free women past menopause in this nonrandomized, open-label study. Before dosing, urine specimens
Roles and clinical applications of OPG and TRAIL as biomarkers in cardiovascular disease.
Bernardi S, et al.
BioMed Research International, 2016, 12-12 (2016)
Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis.
Goswami S and Neelam S-W
BMC Cancer, 15(1), 935-935 (2015)
Functions of RANKL/RANK/OPG in bone modeling and remodeling.
Boyce BF and Xing L.
Archives of Biochemistry and Biophysics, 473(2), 139-146 (2008)
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet WS
Cell, 89(2), 309-319 (1997)

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique